Banque Cantonale Vaudoise Purchases 3,640 Shares of Cencora, Inc. $COR

Banque Cantonale Vaudoise increased its holdings in Cencora, Inc. (NYSE:COR) by 29.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 15,884 shares of the company’s stock after acquiring an additional 3,640 shares during the quarter. Banque Cantonale Vaudoise’s holdings in Cencora were worth $4,964,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. United Bank boosted its stake in shares of Cencora by 4.5% during the second quarter. United Bank now owns 7,032 shares of the company’s stock valued at $2,109,000 after purchasing an additional 305 shares in the last quarter. Savant Capital LLC raised its stake in Cencora by 8.4% in the second quarter. Savant Capital LLC now owns 8,251 shares of the company’s stock worth $2,474,000 after buying an additional 639 shares in the last quarter. Fox Run Management L.L.C. purchased a new stake in Cencora during the second quarter worth $448,000. AE Wealth Management LLC lifted its holdings in Cencora by 6.6% during the second quarter. AE Wealth Management LLC now owns 20,792 shares of the company’s stock worth $6,234,000 after buying an additional 1,283 shares during the period. Finally, Los Angeles Capital Management LLC boosted its position in Cencora by 1,475.4% during the 2nd quarter. Los Angeles Capital Management LLC now owns 13,942 shares of the company’s stock valued at $4,181,000 after acquiring an additional 13,057 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors.

Insider Transactions at Cencora

In related news, EVP Elizabeth S. Campbell sold 3,351 shares of Cencora stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $342.10, for a total value of $1,146,377.10. Following the completion of the sale, the executive vice president directly owned 23,891 shares in the company, valued at $8,173,111.10. This trade represents a 12.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Robert P. Mauch sold 5,096 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the sale, the chief executive officer directly owned 66,726 shares in the company, valued at approximately $23,669,713.98. This represents a 7.10% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 15,220 shares of company stock worth $5,282,867. Insiders own 0.38% of the company’s stock.

Cencora Stock Performance

Shares of COR opened at $361.80 on Tuesday. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62. The firm has a market cap of $70.38 billion, a PE ratio of 43.49, a P/E/G ratio of 1.67 and a beta of 0.68. Cencora, Inc. has a 12 month low of $251.94 and a 12 month high of $377.54. The stock has a fifty day moving average price of $354.60 and a 200-day moving average price of $337.09.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, topping the consensus estimate of $4.04 by $0.04. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The firm had revenue of $85.93 billion for the quarter, compared to the consensus estimate of $86.12 billion. During the same period in the previous year, the business earned $3.73 EPS. The firm’s revenue for the quarter was up 5.5% on a year-over-year basis. Equities research analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, March 2nd. Stockholders of record on Friday, February 13th were paid a dividend of $0.60 per share. The ex-dividend date was Friday, February 13th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s payout ratio is presently 28.85%.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on COR. Barclays lifted their price target on Cencora from $400.00 to $425.00 and gave the company an “overweight” rating in a report on Friday, February 13th. Bank of America dropped their price objective on Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a research report on Monday, January 5th. Weiss Ratings upgraded Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research note on Thursday, February 5th. Jefferies Financial Group upgraded shares of Cencora from an “underperform” rating to a “buy” rating in a report on Thursday, January 22nd. Finally, JPMorgan Chase & Co. increased their price target on shares of Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a research report on Tuesday, February 10th. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, Cencora has a consensus rating of “Moderate Buy” and a consensus price target of $399.00.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.